Endologix Reports 12% Global Revenue Growth for the First Quarter 2014
April 30, 2014 16:01 ET
|
Endologix
Europe Revenue Growth Exceeds 90%
Reiterates 2014 Financial Guidance
IRVINE, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative...
Endologix to Report First Quarter 2014 Financial Results on April 30, 2014
April 21, 2014 16:05 ET
|
Endologix
IRVINE, Calif., April 21, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the...
Endologix to Participate in Two Investor Conferences in March
March 06, 2014 16:05 ET
|
Endologix
IRVINE, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and...
Endologix Reports 25% and 21% Revenue Growth for the Full Year and Fourth Quarter 2013
February 27, 2014 16:05 ET
|
Endologix
IRVINE, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three...
Endologix Announces US Launch of the VELA(TM) Proximal Endograft System
February 10, 2014 09:00 ET
|
Endologix
IRVINE, Calif., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the United States launch of its...
Endologix to Report Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
February 06, 2014 16:15 ET
|
Endologix
IRVINE, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the...
Endologix Announces Enrollment of First Patient in EVAS FORWARD-IDE Clinical Trial
January 21, 2014 09:00 ET
|
Endologix
IRVINE, Calif., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was...
Endologix to Present at the 32nd Annual J.P. Morgan Healthcare Conference
January 06, 2014 09:00 ET
|
Endologix
IRVINE, Calif., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and...
Endologix Receives IDE Approval for the Nellix(R) EndoVascular Aneurysm Sealing System
December 20, 2013 09:00 ET
|
Endologix
IRVINE, Calif., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has received...
Endologix Announces Pricing of $75 Million of Convertible Notes
December 05, 2013 08:30 ET
|
Endologix
IRVINE, Calif., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company") today announced the pricing of its public offering of $75 million aggregate principal...